Curative effect of pemetrexed on the treatment of relapsed primary central nervous system lymphoma.
- Author:
Yong WANG
1
;
Xiuhua WANG
1
;
Yu'e ZHAO
1
;
Rongjie TAO
1
;
Yufang ZHU
1
;
Rongrong ZHAO
1
;
Jun XU
1
Author Information
- Publication Type:Journal Article
- MeSH: Adult; Aged; Central Nervous System Neoplasms; drug therapy; pathology; Female; Glutamates; administration & dosage; adverse effects; therapeutic use; Guanine; administration & dosage; adverse effects; analogs & derivatives; therapeutic use; Humans; Lymphoma, Large B-Cell, Diffuse; drug therapy; pathology; Male; Middle Aged; Neoplasm Recurrence, Local; Pemetrexed; Prognosis; Retrospective Studies
- From: Chinese Journal of Hematology 2014;35(1):46-49
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVETo explore the efficacy and safety of pemetrexed in the treatment of relapsed primary central nervous system lymphoma (PCNSL).
METHODSSeven cases with relapsed PCNSL admitted in our hospital between August 2012 and August 2013 were retrospectively reviewed.
RESULTSOf the 7 relapsed cases, ectopic recurrence occurred in 3, in situ recurrence in 3 and leptomeningeal metastasis in 1. Patients with relapsed PCNSL were administered with high-dose pemetrexed (900 mg/m²) once for every 3 weeks and supplemented with folic acid and vitamin B₁₂. Complete remission was obtained in 2 patients, partial remission in 3 patients and progressive disease in 2. The overall response rate was 71.4% (5/7). The main adverse reactions were myelosuppression and gastrointestinal reaction.
CONCLUSIONTreatment of relapsed PCNSL is difficult, and its prognosis is very poor. Pemetrexed therapy is a meaningful trial.
